Tackling antibiotic resistance: A dose of common antisense?

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 2, 2009, Pages 225-229

  Woodford, Neil ^a,d   Wareham, David W ^b   Chopra, Ian ^c   Ellington, Matthew ^d   Enne, Virve I ^e   Fairhead, Heather ^f   Fraser, William ^g   Gait, Michael J ^h   Lambert, Peter A ^g   Livermore, David M ^d   Neil, Alex J ⁱ   Schneiders, Thamarai ^j   Wareham, D W David W ^b   Yakubu, Davis E ^k  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d HPA Centre for Infections   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f Phico Therapeutics

^g ASTON UNIVERSITY   (United Kingdom)

^h MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

ⁱ University of Edinburgh ^*

^j UNIVERSITY OF EDINBURGH   (United Kingdom)

^k UNIVERSITY OF SUNDERLAND   (United Kingdom)

more..

Author keywords

Bacteriophage; Delivery systems; Modified nucleic acids; Oligonucleotides; Resistance inhibitors modulators

Indexed keywords

ANTIBIOTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BACTERIAL RNA; BETA GALACTOSIDASE; BETA LACTAMASE; CELL PERMEABILITY PEPTIDE; DRUG CARRIER; OLIGONUCLEOTIDE; PEPTIDE NUCLEIC ACID; PHOSPHORODIAMIDATE MORPHOLINO OLIGONUCLEOTIDE; RNA 23S; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTISENSE THERAPY; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL STRAIN; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG UPTAKE; EDITORIAL; ENTEROCOCCUS; ESCHERICHIA COLI K 12; GENE TARGETING; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; ANTISENSE ELEMENTS (GENETICS); BACTERIA; DRUG RESISTANCE, BACTERIAL; GENE SILENCING; HUMANS;

EID: 58849145635     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn467     Document Type: Editorial

References (38)

1. Fox JL. The business of developing antibacterials. Nat Biotechnol 2006; 24: 1521-8.
2. Projan SJ, Shlaes DM. Antibacterial drug discovery: Is it all downhill from here? Clin Microbiol Infect 2004; 10 Suppl 4: 18-22.
3. Wall NR, Shi Y. Small RNA: Can RNA interference be exploited for therapy? Lancet 2003; 362: 1401-3.
4. van Ommen GJ, van Deutekom J, Aartsma-Rus A. The therapeutic potential of antisense-mediated exon skipping. Curr Opin Mol Ther 2008; 10: 140-9.
5. Wacheck V. Oligonucleotide therapeutics - an emerging novel class of compounds. Wien Med Wochenschr 2006; 156: 481-7.
6. Chopra I. Prospects for antisense agents in the therapy of bacterial infections. Expert Opin Investig Drugs 1999; 8: 1203-8.
7. Good L. Antisense antibacterials. Expert Opin Ther Patents 2002; 12: 1173-9.
8. Geller BL. Antibacterial antisense. Curr Opin Mol Ther 2005; 7 109-13.
9. Kurupati P, Tan KSW, Kumarasinghe G et al. Inhibition of gene expression and growth by antisense peptide nucleic acids in a multiresistant β-lactamase-producing Klebsiella pneumoniae strain. Antimicrob Agents Chemother 2007; 51: 805-11.
10. Nekhotiaeva N, Awasthi SK, Nielsen PE et al. Inhibition of Staphylococcus aureus gene expression and growth using antisense peptide nucleic acids. Mol Ther 2004; 10: 652-9.
11. Sarno R, Ha H, Weinsetel N et al. Inhibition of aminoglycoside 60-N-acetyltransferase type Ib-mediated amikacin resistance by antisense oligodeoxynucleotides. Antimicrob Agents Chemother 2003; 47: 3296-304.
12. Soler Bistué AJC, Ha H, Sarno R et al. External guide sequences targeting the aac(6′)- Ib mRNA induce inhibition of amikacin resistance. Antimicrob Agents Chemother 2007; 51: 1918-25.
13. Gao MY, Xu CR, Chen R et al. Chloromycetin resistance of clinically isolated E coli is conversed by using EGS technique to repress the chloromycetin acetyl transferase. World J Gastroenterol 2005; 11: 7368-73.
14. White DG, Maneewannakul K, von Hofe E et al. Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs. Antimicrob Agents Chemother 1997; 41: 2699-704.
15. Torres VC, Tsiodras S, Gold HS et al. Restoration of vancomycin susceptibility in Enterococcus faecalis by antiresistance determinant gene transfer. Antimicrob Agents Chemother 2001; 45 973-5.
16. Livermore DM, Mushtaq S, Warner M et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. J Antimicrob Chemother 2008; 62: 1053-6.
17. Stavri M, Piddock LJV, Gibbons S. Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother 2007; 59: 1247-60.
18. Delihas N. Regulation of gene expression by trans-encoded anti-sense RNAs. Mol Microbiol 1995; 15: 411-4.
19. Romby P, Vandenesch F, Wagner EG. The role of RNAs in the regulation of virulence-gene expression. Curr Opin Microbiol 2006; 9: 229-36.
20. Chen G, Patten CL, Schellhorn HE. Controlled expression of an rpoS antisense RNA can inhibit RpoS function in Escherichia coli. Antimicrob Agents Chemother 2003; 47: 3485-93.
21. Ecker DJ, Freier SM. PNA, antisense, and antimicrobials. Nat Biotechnol 1998; 16: 332.
22. Mojzisek M. Triplex forming oligonucleotides - tool for gene targeting. Acta Medica (Hradec Kralove) 2004; 47: 151-6.
23. Hojland T, Kumar S, Babu BR et al. LNA (locked nucleic acid) and analogs as triplex-forming oligonucleotides. Org Biomol Chem 2007; 5: 2375-9.
24. Lebleu B, Moulton HM, Abes R et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 2008; 60: 517-29.
25. Warfield KL, Panchal RG, Aman MJ et al. Antisense treatments for biothreat agents. Curr Opin Mol Ther 2006; 8: 93-103.
26. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003; 270: 1628-44.
27. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003; 31: 3406-15.
28. Ding Y, Lawrence CE. A statistical sampling algorithm for RNA secondary structure prediction. Nucleic Acids Res 2003; 31: 7280-301.
29. Ding Y, Chan CY, Lawrence CE. Sfold web server for statistical folding and rational design of nucleic acids. Nucl Acids Res 2004; 32 W135-41.
30. Shao Y, Wu Y, Chan CY et al. Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation. Nucleic Acids Res 2006; 34: 5660-9.
31. Hammond SM, Claesson A, Jansson AM et al. A new class of synthetic antibacterials acting on lipopolysaccharide biosynthesis. Nature 1987; 327: 730-2.
32. Dryselius R, Nekhotiaeva N, Good L. Antimicrobial synergy between mRNA- and protein-level inhibitors. J Antimicrob Chemother 2005; 56 97-103.
33. Geller BL, Deere JD, Stein DA et al. Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers. Antimicrob Agents Chemother 2003; 47: 3233-9.
34. Nikravesh A, Dryselius R, Faridani OR et al. Antisense PNA accumulates in Escherichia coli and mediates a long post-antibiotic effect. Mol Ther 2007; 15: 1537-42.
35. Tan XX, Actor JK, Chen Y. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: Proof of principle using mouse intraperitoneal infection. Antimicrob Agents Chemother 2005; 49: 3203-7.
36. Vaara M, Porro M. Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob Agents Chemother 1996; 40: 1801-5.
37. Tilley LD, Mellbye BL, Puckett SE et al. Antisense peptide-phosphorodiamidate morpholino oligomer conjugate: Dose-response in mice infected with Escherichia coli. J Antimicrob Chemother 2007; 59: 66-73.
38. Rasmussen L, Sperling-Petersen H, Mortensen K. Hitting bacteria at the heart of the central dogma: Sequence-specific inhibition. Microb Cell Factories 2007; 6: 24.